SCHEMBL4568545

SCHEMBL4568545

CCCc1cccc(-c2[nH]c3cc(OC)ccc3c2Cc2cccc(C(=O)O)n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR17 Q13304 1/20 0.42
MTNR1A P48039 3/20 0.40
MTNR1B P49286 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PPARG P37231 2/20 0.39
TUBB4A P04350 2/20 0.39
TUBB P07437 2/20 0.39
TUBA3C P0DPH7 2/20 0.39
TUBA1B P68363 2/20 0.39
TUBA4A P68366 2/20 0.39
TUBB4B P68371 2/20 0.39
TUBB3 Q13509 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4568540 0.93 GPR17 (0.41) GPR17MTNR1AMTNR1BCYP1A2CYP3A4
SCHEMBL4568436 0.92 MTNR1A (0.39) GPR17MTNR1AMTNR1BCYP1A2CYP3A4
SCHEMBL3704461 0.90 GPR17 (0.44) GPR17MTNR1AMTNR1BCYP1A2CYP3A4
SCHEMBL3702535 0.89 TUBB4A (0.48) GPR17MTNR1AMTNR1BCYP1A2CYP3A4
SCHEMBL4568211 0.87 PTGS2 (0.44) GPR17MTNR1AMTNR1BCYP1A2CYP3A4
SCHEMBL3712236 0.86 MAPK13 (0.52) GPR17KDM4EALDH1A1HPGDTUBB4A
SCHEMBL3716974 0.86 MAPK13 (0.52) GPR17TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4568432 0.86 PLA2G2A (0.40) MTNR1AMTNR1BCYP1A2CYP3A4CYP2D6
SCHEMBL3711669 0.85 CYP19A1 (0.42) GPR17MTNR1AMTNR1BKDM4E
SCHEMBL4568208 0.84 MDM4 (0.44) GPR17MTNR1AMTNR1BCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2474530-B1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL (JP) 2014-09-03 EP disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122931-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R GPR17 59/4885MTNR1A 19/4885MTNR1B 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.